Screening for insulin resistance in women with polycystic ovarian syndrome

Gynecological Endocrinology

Volumn 20, Issue 2, 2005, Pages 84-91

  Heald, Adrian H ^a   Whitehead, Sharon ^a   Anderson, Simon ^a   Cruickshank, Kennedy ^a   Riste, Lisa ^a   Laing, Ian ^b   Rudenski, Aram ^a   Buckler, Helen ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Homeostasis model assessment modelling; Insulin resistance; Polycystic ovarian syndrome

Indexed keywords

FOLLITROPIN; GLUCOSE; HYDROXYPROGESTERONE; INSULIN; INSULIN SENSITIZING AGENT; PRASTERONE SULFATE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; THYROXINE;

ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HIRSUTISM; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; IMPAIRED GLUCOSE TOLERANCE; INFERTILITY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OLIGOMENORRHEA; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME;

EID: 18044362752     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/09513590400021045     Document Type: Article

References (33)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azzizet R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-3082.
2. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333:853-861.
3. Burghen GA, Givens JR, Kitabehi AE. Correlation of hyperandrogenism with hyperinsulinaemia in polycystic ovarian disease. J Clin Endocrinol Metab 1980;50:113-116.
4. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169.
5. Lobo RA, Carmina E. The importance of diagnosing the polycystic syndrome. Ann Intern Med 2000;1:32:989-993.
6. Ciaraldi TP, el Roeiy A, Madar Z, Reichart D, Olefsky JM, Yen SSC. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 1992;75:577-583.
7. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995;96:801-810.
8. Jahanfar S, Eden JA, Warren P, Seppälä M, Nguyen TV. A twin study of polycystic ovary syndrome. Fertil Steril 1995; 63:478-486.
9. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Nestler JE. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003;88:1927-1932.
10. Campbell PJ, Gerich JE. Impact of obesity on insulin action in volunteers with normal glucose tolerance: demonstration of a threshold for the adverse effect of obesity. J Clin Endocrinol Metab 1990;70:1114-1118.
11. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin-induced resumption of normal menses in 39 of 41 (91%) previously amenorrhoeic women with the polycystic ovary syndrome. Metabolism 1999;48:511-519.
12. Unluhizarci K, Kelestimur F, Bayram F, Sahin Y, Tutus A. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol 1999;51:231-236.
13. Chevenne D, Trivin F, Porquet D. Insulin assays and reference values. Diabetes Metab 1999;25:459-476.
14. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovarian syndrome. N Engl J Med 1998;338:1876-1880.
15. Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767-2774.
16. Taylor AE. Insulin-lowering medications in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2000;27:583-595.
17. Riste L, Khan F, Cruickshank K. High prevalence of type 2 diabetes in all ethnic groups, including Europeans, in a British inner city: relative poverty, history, inactivity or 21st century Europe. Diabetes Care 2001;24:1377-1383.
18. World Health Organization. Guidelines for diabetes. Geneva: WHO: 2000 Jun.
19. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-1447.
20. Matthews DR, Hosker JB, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
21. Rudenski AS, Matthews DR, Levy JC, Turner RC. Understanding 'insulin resistance': both glucose resistance and insulin resistance are required to model human diabetes. Metabolism 1991;40:908-917.
22. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990;300:230-235.
23. Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens 1998;16:895-906.
24. Rudenski AS, Hadden DR, Atkinson AB, Kennedy L, Matthews DR, Merrett JD, Pockaj B, Turner RC. Natural history of pancreatic islet B-cell function in type 2 diabetes mellitus studied over six years by homeostasis model assessment. Diabetic Medicine 1988;5:36-41.
25. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987;65:499-507.
26. Poison DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries - a common finding in normal women. Lancet 1988;l:870-872.
27. Nestler JE. Sex hormone-binding globulin: a marker for hyperinsulinemia and/or insulin resistance? J Clin Endocrinol Metab 1993;76:273-274.
28. Sattar N, Hopkinson ZE, Greer IA. Insulin-sensitising agents in polycystic-ovary syndrome. Lancet 1998;354:305-307.
29. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS. Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:4649-4654.
30. Jayagopal V, Kilpatrick ES, Jennings PE, Hepburn DA, Atkin SL. The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. J Clin Endocrinol Metab 2003;88:1528-1533.
31. Heald AH, Cruickshank JK, Riste LK, Cade JE, Anderson S, Greenhalgh A, Sampayo J, Taylor W, Fraser W, White A, et al. Close relationship of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in 2 populations. Diabetologia 2001;44: 333-339.
32. Morris DV, Falcone T. The relationship between insulin sensitivity and insulin-like growth factor-binding protein-1. Gynecol Endocrinol 1996;10:407-412.
33. Kelly CJ, Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol 2002;147:217-221.